SARS-CoV-2 InfectionBREATH-COVNCT07063134
Chronic Mouth Breathing and SARS-CoV-2 Positivity in the Pediatric Population
An observational study of SARS-CoV-2 Infection, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).
Trial summary
Numerous non-scientific articles on the internet assert the significance of nasal breathing in protecting against COVID-19. Although nasal breathing is anticipated to result in a reduced intake of bioparticles when compared to mouth breathing due to the filtering mechanisms present in the nasal cavity, we have yet to… Read more about this study
- Who is it for?
- Ages 10 to 18 hours
- Conditions the study is for
- SARS-CoV-2 Infection
- How many people
- 173 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Mar 2022to 2 May 2022
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 hours
- All sexes
- No healthy volunteers
- Child
Study population: A total of 173 patients aged between 10 and 17 years, without any systemic diseases or COVID-19 vaccinations, who were undergoing COVID-19 testing, were included in the study.
Who may be able to join
- tested for COVID-19
Who cannot join
- Not tested for COVID-19
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Investigation of the Relationship Between Chronic Mouth Breathing and SARS-CoV-2 Positivity in the Pediatric Population
Numerous non-scientific articles on the internet assert the significance of nasal breathing in protecting against COVID-19. Although nasal breathing is anticipated to result in a reduced intake of bioparticles when compared to mouth breathing due to the filtering mechanisms present in the nasal cavity, we have yet to identify any in vivo studies within the literature that definitively ascertain the correlation between mouth breathing and COVID-19 positivity. Consequently, this study aimed to investigate the impact of chronic mouth breathing on testing positive for COVID-19 in children.
Read the detailed description
Objective Coronavirus disease (COVID-19) is an infectious respiratory illness caused by the SARS-CoV-2 virus. Breathing patterns may influence the transmission of respiratory diseases. Mouth breathing inhaled pollutants and pathogens directly into the lungs. Therefore, this research investigated the impact of chronic mouth breathing on COVID-19 positivity in children.
Materials and Methods A total of 173 patients aged between 10 and 17 years, without any systemic diseases or COVID-19 vaccinations, who were undergoing COVID-19 testing, were included in the study. The age, gender, simplified oral hygiene index, and respiratory models of the included patients were assessed. Patients with a specific malocclusion caused by mouth breathing were diagnosed as "mouth breathers" through clinical assessments. Those who tested positive for COVID-19 were assigned to the experimental group, while those who tested negative were designated as the control group. The differences in mouth breathing rates, simplified oral hygiene index, and sociodemographic data (sex and age) between groups were statistically analysed. Subsequently, the relationship between mouth breathing and the Delta variant was examined.
Results No statistically significant differences were found in sex, breathing pattern, and the simplified oral hygiene index, except for age (p>0.05). The average age of the patients in the experimental group was lower. The Delta variant was more common among chronic mouth breathers (p<0.05).
Conclusion Chronic mouth breathing heightens the risk of transmission, as the pathogenicity of COVID-19 viruses increases.
Clinical relevance Healthcare professionals should possess the knowledge necessary to identify individuals who breathe through their mouths, as this group faces a heightened risk of contracting respiratory diseases.
- Conditions
- SARS-CoV-2 Infection
- Keywords
- Coronavirus- Mouth breathing - Nasal breathing - Delta variant
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COVID-19 Positive Group | Participants who tested positive for SARS-CoV-2 by PCR at the time of evaluation. | |
| COVID-19 Negative Group | Participants who tested negative for SARS-CoV-2 by PCR at the time of evaluation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of COVID-19 Positivity in Chronic Mouth Breathers Compared to Nasal Breathers
Proportion of COVID-19 positivity among chronic mouth breathers compared to nasal breathers
Measured: At 2 weeks post-COVID-19 recovery"
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start2 Mar 2022
- Primary completion5 Mar 2022
- Study completion2 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SARS-CoV-2 InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 173 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Dokuz Eylul University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Serap Titiz Yurdakal, Dokuz Eylul University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07063134
- Sponsor's protocol ID
- DEUORTO-CMB-2025
- Acronym
- BREATH-COV
- Status last verified
- Jun 2025
- First submitted
- 26 Jun 2025
- Last updated
- 14 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Relationship Between Chronic Mouth Breathing and SARS-CoV-2 Positivity in the Pediatric Population
- ClinicalTrials.gov ID
- NCT07063134
- Acronym / sponsor ID
- BREATH-COV / DEUORTO-CMB-2025
- Conditions
- SARS-CoV-2 Infection
- Keywords
- Coronavirus- Mouth breathing - Nasal breathing - Delta variant
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 173 participants (actual)
- Lead sponsor
- Dokuz Eylul UniversityUniversity, hospital or other
- Study start
- 2 Mar 2022 (actual)
- Primary completion
- 5 Mar 2022 (actual)
- Study completion
- 2 May 2022 (actual)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Numerous non-scientific articles on the internet assert the significance of nasal breathing in protecting against COVID-19. Although nasal breathing is anticipated to result in a reduced intake of bioparticles when compared to mouth breathing due to the filtering mechanisms present in the nasal cavity, we have yet to identify any in vivo studies within the literature that definitively ascertain the correlation between mouth breathing and COVID-19 positivity. Consequently, this study aimed to investigate the impact of chronic mouth breathing on testing positive for COVID-19 in children.
Detailed description
Objective Coronavirus disease (COVID-19) is an infectious respiratory illness caused by the SARS-CoV-2 virus. Breathing patterns may influence the transmission of respiratory diseases. Mouth breathing inhaled pollutants and pathogens directly into the lungs. Therefore, this research investigated the impact of chronic mouth breathing on COVID-19 positivity in children.
Materials and Methods A total of 173 patients aged between 10 and 17 years, without any systemic diseases or COVID-19 vaccinations, who were undergoing COVID-19 testing, were included in the study. The age, gender, simplified oral hygiene index, and respiratory models of the included patients were assessed. Patients with a specific malocclusion caused by mouth breathing were diagnosed as "mouth breathers" through clinical assessments. Those who tested positive for COVID-19 were assigned to the experimental group, while those who tested negative were designated as the control group. The differences in mouth breathing rates, simplified oral hygiene index, and sociodemographic data (sex and age) between groups were statistically analysed. Subsequently, the relationship between mouth breathing and the Delta variant was examined.
Results No statistically significant differences were found in sex, breathing pattern, and the simplified oral hygiene index, except for age (p>0.05). The average age of the patients in the experimental group was lower. The Delta variant was more common among chronic mouth breathers (p<0.05).
Conclusion Chronic mouth breathing heightens the risk of transmission, as the pathogenicity of COVID-19 viruses increases.
Clinical relevance Healthcare professionals should possess the knowledge necessary to identify individuals who breathe through their mouths, as this group faces a heightened risk of contracting respiratory diseases.
Study design
- Observational model
- Other
- Time perspective
- Other
- Target follow-up
- 1 Day
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| COVID-19 Positive Group | – | –Participants who tested positive for SARS-CoV-2 by PCR at the time of evaluation. |
| COVID-19 Negative Group | – | –Participants who tested negative for SARS-CoV-2 by PCR at the time of evaluation. |
Who may qualify
- Ages
- 10 to 18 hours
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- A total of 173 patients aged between 10 and 17 years, without any systemic diseases or COVID-19 vaccinations, who were undergoing COVID-19 testing, were included in the study.
Key inclusion criteria (1 listed)
- tested for COVID-19
Key exclusion criteria (1 listed)
- Not tested for COVID-19
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Rate of COVID-19 Positivity in Chronic Mouth Breathers Compared to Nasal Breathers
Time frame: At 2 weeks post-COVID-19 recovery"
Proportion of COVID-19 positivity among chronic mouth breathers compared to nasal breathers
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2025.
- Individual participant dataSharing planned: Undecided
Related trials for SARS-CoV-2 Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of SARS-CoV-2 Infection, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of COVID-19 Positivity in Chronic Mouth Breathers Compared to Nasal Breathers (time frame: At 2 weeks post-COVID-19 recovery"). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2025.